Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemokine Receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Chemokine Receptor. Displaying page 1 of 1.
    EudraCT Number: 2004-002567-24 Sponsor Protocol Number: M120204-063 Start Date*: 2005-04-04
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis
    Medical condition: The purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003332-23 Sponsor Protocol Number: B1261007 Start Date*: 2013-03-21
    Sponsor Name:Pfizer Inc., 235 42nd Street, New York, NY 10017, USA
    Full Title: A phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonis...
    Medical condition: Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) ES (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-000241-21 Sponsor Protocol Number: BEL114870 Start Date*: 2011-06-23
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A clinical and mechanistic proof of efficacy study with belimumab in chronic immune thrombocytopenia (ITP) patients
    Medical condition: Chronic Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10051057 Idiopathic thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001779-20 Sponsor Protocol Number: A4001029 Start Date*: 2005-02-02
    Sponsor Name:Pfizer Limited
    Full Title: A multicentre, randomised, double-blind, placebo-controlled trial of novel CCR5 antagonist, UK-427,857, in comination with optimised background therapy versus optimised background therapy alone for...
    Medical condition: UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in individuals HIV-1 positive.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001696-36 Sponsor Protocol Number: IL2REG Start Date*: 2019-10-09
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Study of efficacy of low-dose recombinant human interleukin-2 in immunological changes associated with depression (IL2REG)
    Medical condition: Depressive episode in course of mood disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10012402 Depressive episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002989-33 Sponsor Protocol Number: COLPRIT-0000-BAS-0041-I Start Date*: 2023-06-29
    Sponsor Name:Klinikum rechts der Isar der Technischen Universität München
    Full Title: CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY: THE COLPRIT PHASE I/II STUDY
    Medical condition: Indication: Non-Hodgkin lymphomas (NHL) Advanced lymphoproliferative cancers: aggressive B- and T- cell Non-Hodgkin lymphomas (NHL), including heavily pretreated transformed indolent lymphoma (tNHL...
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003147-27 Sponsor Protocol Number: B1261009 Start Date*: 2014-01-10
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY 10017 US
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) WITH THAT OF ...
    Medical condition: PF-04634817 is a small molecule chemokine CCR2/5 receptor antagonist that is being developed for the treatment of diabetic nephropathy and diabetic macular edema.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10057934 Diabetic macular edema LLT
    18.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002356-27 Sponsor Protocol Number: XCGD_MOBI1 Start Date*: 2015-10-16
    Sponsor Name:Ospedale San Raffaele
    Full Title: A multicentric, exploratory, non-randomised, non-controlled, prospective, open-label phase II, study evaluating safety and efficacy of IBU, G-CSF and Plerixafor as a stem cell mobilization regimen ...
    Medical condition: X-linked chronic granulomatous disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10008906 Chronic granulomatous disease PT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001778-21 Sponsor Protocol Number: A4001028 Start Date*: 2005-02-02
    Sponsor Name:PFIZER LTD
    Full Title: A multicentre, randomised, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857 in combination with optimised background therapy versus optimised background therapy alone f...
    Medical condition: UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002243-15 Sponsor Protocol Number: IMCnyeso-101 Start Date*: 2018-10-04
    Sponsor Name:Immunocore Ltd.
    Full Title: A Phase I/II Open-Label, Multi-center Study of the Safety and Efficacy of IMCnyeso, an HLA-A* 0201-Restricted, NY-ESO-1 and LAGE-1A-specific soluble T Cell Receptor and Anti-CD3 Bi-specific Molecul...
    Medical condition: HLA-A*0201 positive patients with advanced antigen-positive cancer with a histologic diagnosis of Non small cell lung carcinoma (NSCLC), melanoma, urothelial carcinoma, or synovial sarcoma with an...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025665 Malignant melanoma of skin stage unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-003951-44 Sponsor Protocol Number: ΕΑΕ-2017/ΜΜ01 Start Date*: 2017-12-15
    Sponsor Name:Hellenic Society of Hematology
    Full Title: A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and /or Refractory Multiple M...
    Medical condition: Relapsed and /or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002872-14 Sponsor Protocol Number: VAC079 Start Date*: 2019-11-12
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: A Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1 in healthy adults living in the UK
    Medical condition: Plasmodium vivax malaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10047665 Vivax malaria (benign tertian) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-000643-27 Sponsor Protocol Number: VAC071 Start Date*: 2019-09-23
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: A Phase IIa challenge study to assess efficacy of the Plasmodium vivax malaria vaccine candidates ChAd63 PvDBP and MVA PvDBP in healthy adults living in the UK
    Medical condition: Plasmodium vivax malaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10047665 Vivax malaria (benign tertian) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-001914-15 Sponsor Protocol Number: A4001026 Start Date*: 2008-02-07
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A multicentre, randomised, double-blind, comparative trial of a novel CCR5 antagonist, UK427,857, in combination with zidovudine/lamivudine versus efavirenz in combination with zidovudine/lamivudin...
    Medical condition: UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-006165-14 Sponsor Protocol Number: C08005 Start Date*: 2006-08-03
    Sponsor Name:Millennium Pharmaceuticals Inc,
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of the Efficacy, Safety, and Pharmacokinetics of MLN3897 in Patients with Rheumatoid Arthritis Taking Methotrexate
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-001866-15 Sponsor Protocol Number: 1182.71 Start Date*: 2007-07-12
    Sponsor Name:Boehringer Ingelheim France SAS
    Full Title: A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in three-clas...
    Medical condition: HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Prematurely Ended) GR (Completed) PT (Prematurely Ended) IT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002623-11 Sponsor Protocol Number: 213500 Start Date*: 2020-12-18
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravi...
    Medical condition: Human Immunodeficiency Virus Type-1 (HIV-1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10003582 Asymptomatic human immunodeficiency virus type I infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IE (Completed) DE (Completed) AT (Completed) IT (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004372-22 Sponsor Protocol Number: Ti-061-101 Start Date*: 2017-04-05
    Sponsor Name:Tioma Therapeutics, Inc.
    Full Title: A Phase 1-2 Study of Ti-061 Alone and in combination with other anti-cancer agents in Patients with Advanced Malignancies
    Medical condition: Advanced malignancies
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024332-42 Sponsor Protocol Number: BAY63-2521/13605 Start Date*: 2014-04-10
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmon...
    Medical condition: pulmonary hypertension associated with idiopathic interstitial pneumonias
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) BE (Completed) GB (Completed) PT (Completed) DK (Completed) GR (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 04:15:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA